These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
Market Analysis and Price Projections for NDC 66758-0087
Last updated: February 23, 2026
What is the drug identified by NDC 66758-0087?
NDC 66758-0087 corresponds to Xywav (calcium, magnesium, and potassium oxalate formulations of sodium oxybate). It is approved by the FDA primarily for the treatment of narcolepsy with cataplexy and idiopathic hypersomnia.
Market Overview
Regulatory and Approval Status
FDA Approval Date: December 2019
Indications: Narcolepsy with cataplexy, idiopathic hypersomnia
Manufactured by: Jazz Pharmaceuticals
Market Adoption
Xywav replaced the older formulation, XYREM (sodium oxybate), with a lower sodium content aimed at reducing cardiovascular risks.
Estimated market penetration has increased due to expanded indications, especially for idiopathic hypersomnia.
Competitive Landscape
Main competitor: Sodium oxybate (XYREM)
Other treatments for narcolepsy and hypersomnia include stimulants (e.g., modafinil, armodafinil), solriamfetol, and pitolisant.
The utilization of Xywav depends on physicians' preference for reduced sodium formulation and patient response.
Price Metrics and Projections
Current Pricing Information
Average Wholesale Price (AWP): Approximately $49,200 per year (per patient, based on typical dosing)
List Price: Approx. $45,000 - $55,000 annually
Patient Access Programs: Significant discounts via patient assistance programs and specialty pharmacy negotiations
Revenue Estimates
Initial sales (2020-2022): Approximately $150 million annually
Projected growth: 10-15% CAGR over the next five years, given expanding indications and increased diagnosis rates
Price Trends
The list price has remained relatively stable since launch, but net prices vary due to rebates, discounts, and insurance negotiations.
Price reductions are expected in response to increased competition and potential biosimilar/equivalent entrants.
The emergence of biosimilars or generic formulations
Shifts in clinical guidelines favoring alternative therapies
Conclusions
The U.S. market for Xywav is expected to grow steadily, driven by expanding indications and increased diagnosis.
Current list prices are stable, but net prices face downward pressure from competition and payor negotiations.
Revenue projections suggest a 10-15% annual growth rate over the next five years, assuming regulatory and market dynamics remain stable.
Key Takeaways
NDC 66758-0087 (Xywav) is a low-sodium oxybate for narcolepsy and hypersomnia.
Market penetration is increasing, with revenues approximating $150 million annually.
Pricing remains high; net prices are influenced heavily by insurance rebates.
Growth prospects depend on expanding indications, competitive pressures, and regulatory developments.
Future price reductions could occur if biosimilars or generics enter the market.
FAQs
What is the main differentiator of Xywav compared to XYREM?
Xywav contains a lower sodium content, reducing cardiovascular risk and expanding its suitability for a broader patient population.
How is the pricing of Xywav expected to change in the coming years?
List prices are likely stable, but net prices may decline due to competition and payor negotiations. Revenue growth depends on increased adoption and positive clinical outcomes.
What are the major competitors for Xywav?
Stimulant medications like modafinil and armodafinil, solriamfetol, and pitolisant serve as alternative treatments for narcolepsy and hypersomnia.
Can insurance coverage significantly affect Xywav’s pricing?
Yes; insurance rebates, co-pay assistance, and coverage policies substantially influence the net cost to payors and patients.
What are the key risks that could impact Xywav market share?
Patent challenges, biosimilar entry, regulatory restrictions, or shifts in clinical guidelines favoring other therapies could affect market share.
References
U.S. Food and Drug Administration. (2019). Xywav approval announcement. FDA.gov.
Jazz Pharmaceuticals. (2022). Xywav prescribing information.
IQVIA. (2023). U.S. pharmaceutical market data.
SSR Health. (2023). Medicare Part D net prices for specialty drugs.
Evaluate Pharma. (2023). 5-year forecasts for CNS therapeutics.
(Note: Exact prices and revenue figures are estimates based on available public sources and market trends; actual figures vary with negotiated discounts and regional differences.)
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
